Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 353.86 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2009 | 2.74 Million USD | 118.28% |
| 2008 | 1.25 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q4 | 353.86 Thousand USD | 15.17% |
| 2023 Q2 | 263.1 Thousand USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q3 | 307.25 Thousand USD | 16.78% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2010 Q2 | 3.79 Million USD | 53.24% |
| 2010 Q1 | 2.47 Million USD | 2212377.32% |
| 2009 Q4 | 111.89 USD | 0.0% |
| 2009 FY | 2.74 Million USD | 118.28% |
| 2008 FY | 1.25 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| America Great Health | 1.87 Million USD | 81.079% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -29.149% |
| Aridis Pharmaceuticals, Inc. | 6.13 Million USD | 94.227% |
| Biora Therapeutics, Inc. | 47.42 Million USD | 99.254% |
| Bio-Path Holdings, Inc. | 113 Thousand USD | -213.158% |
| Better Therapeutics, Inc. | 14.88 Million USD | 97.622% |
| Calithera Biosciences, Inc. | 1.66 Million USD | 78.759% |
| Comera Life Sciences Holdings, Inc. | 775.04 Thousand USD | 54.342% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 19.44 Million USD | 98.18% |
| Eloxx Pharmaceuticals, Inc. | 13.38 Million USD | 97.356% |
| Evelo Biosciences, Inc. | 51.13 Million USD | 99.308% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 90.548% |
| Finch Therapeutics Group, Inc. | 30.12 Million USD | 98.825% |
| Galera Therapeutics, Inc. | 152.29 Million USD | 99.768% |
| Innovation1 Biotech Inc. | 228.99 Thousand USD | -54.528% |
| Kiromic BioPharma, Inc. | 15.54 Million USD | 97.723% |
| Molecular Templates, Inc. | 12.23 Million USD | 97.107% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 85.463% |
| NexImmune, Inc. | 68.8 Thousand USD | -414.276% |
| Orgenesis Inc. | 22.62 Million USD | 98.436% |
| Panbela Therapeutics, Inc. | 5.19 Million USD | 93.187% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 134.5 Million USD | 99.737% |
| Statera Biopharma, Inc. | 16.26 Million USD | 97.824% |
| TRACON Pharmaceuticals, Inc. | 968 Thousand USD | 63.443% |
| Trevena, Inc. | 35.23 Million USD | 98.996% |
| Vaxxinity, Inc. | 15.16 Million USD | 97.667% |
| Vaccinex, Inc. | 247 Thousand USD | -43.266% |
| Viracta Therapeutics, Inc. | 25.55 Million USD | 98.615% |
| ZIVO Bioscience, Inc. | 346.34 Thousand USD | -2.173% |